ClinicalTrials.gg
CompletedNCT06097273Updated Jul 1, 2025Results posted

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

A Phase 3 interventional study of mRNA-1083 and Placebo in SARS-CoV-2 and Influenza, sponsored by ModernaTX, Inc.. Completed at 146 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,061
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Influenza, Human by Moderna, Inc. — 2 open to participants now, 3 under way, 1 of them phase 3. Influenza, Human · Moderna, Inc..

Enrollment
4th of 23
8,061 · median 885
Started
2023
with 5 others
Phase 3
7 of 23
none open now
Registered
16th of 23
by date

Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 4th largest by enrollment, is one of 6 that started in 2023, is one of 7 in phase 3, and was the 16th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 23 studies in Influenza, Human by Moderna, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Influenza, Human by Moderna, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).

03

Conditions studied

  • SARS-CoV-2
  • Influenza

Keywords

  • mRNA-1083
  • mRNA-1083 Vaccine
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • Influenza Vaccine
  • Moderna
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy adults either ≥65 years of age (Cohort A) or 50 to \<65 years of age (Cohort B) at the time of consent (Screening Visit).
  • For female participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, and agreement to continue adequate contraception through 3 months following vaccine administration.
  • Fully vaccinated for COVID-19 primary series according to the locally authorized or approved regimen, and their last COVID-19 vaccine (primary series or booster) was ≥90 days prior to Day 1.

Exclusion Criteria:

  • Participant is acutely ill or febrile (temperature ≥38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1.
  • Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Participant has received systemic for >14 days in total within 180 days prior to Day 1 (for , ≥10 milligrams [mg]/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study. Inhaled nasal and topical steroids are allowed.
  • Received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to study injections or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections.
  • Received a seasonal influenza vaccine ≤150 days prior to Day 1.
  • Tested positive for influenza by local health authority-approved testing methods ≤150 days prior to Day 1.
  • Has had close contact to someone with COVID-19 as defined by the Centers for Disease Control and Prevention (CDC) in the past 10 days prior to Day 1.
  • Has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8,061 participants (actual)

Study arms

  • Experimental
    Cohort A1: mRNA-1083 and Placebo

    Participants of age 65 years and older will receive mRNA-1083 and placebo administered as 2 intramuscular (IM) injections of on Day 1.

    Biological: mRNA-1083 · Biological: Placebo

  • Active comparator
    Cohort A2: Influenza Vaccine and COVID-19 Vaccine

    Participants of age 65 years and older will receive age recommended quadrivalent influenza vaccine and COVID-19 vaccine administered as 2 IM injections on Day 1.

    Biological: Influenza Vaccine · Biological: COVID-19 Vaccine

  • Experimental
    Cohort B1: mRNA-1083 and Placebo

    Participants of age 50 to \<65 years will receive mRNA-1083 and placebo administered as 2 IM injections of on Day 1.

    Biological: mRNA-1083 · Biological: Placebo

  • Active comparator
    Cohort B2: Influenza Vaccine and COVID-19 Vaccine

    Participants of age 50 to \<65 years will receive age recommended quadrivalent influenza vaccine and COVID-19 vaccine administered as 2 IM injections on Day 1.

    Biological: Influenza Vaccine · Biological: COVID-19 Vaccine

Interventions

  • BiologicalmRNA-1083

    Suspension for injection

  • BiologicalPlacebo

    0.9% sodium chloride suspension for injection

  • BiologicalInfluenza Vaccine

    Commercially available formulation (Suspension for injection \[pre-filled syringe\])

  • BiologicalCOVID-19 Vaccine

    Commercially available formulation (Suspension for injection)

06

What researchers measure

Primary outcomes

  1. Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. The Per Protocol Immunogenicity Set (PPIS) included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative reverse transcription polymerase chain reaction (RT-PCR) test for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

    Time frame: Day 29

  2. GM Level of Antibodies for SARS-CoV-2, as Measured by Pseudovirus Neutralization Assay (PsVNA)

    SARS-CoV-2 strain included Omicron XBB.1.5 antibody. The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

    Time frame: Day 29

  3. Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a Day 29 postinjection level ≥1:40 if Baseline was \<1:10 or a 4-fold or greater rise if Baseline was ≥1:10 in anti-hemagglutinin (HA) antibodies measured by HAI assay. The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

    Time frame: Baseline to Day 29

  4. SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA

    SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as a Day 29 postinjection level ≥4-fold rise if Baseline was ≥lower limit of quantification (LLOQ) or ≥4×LLOQ if Baseline value was \<LLOQ in the nAb values measured by PsVNA. LLOQ was 38 arbitrary unit (AU)/milliliter (mL). The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

    Time frame: Baseline to Day 29

  5. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs (local and systemic) were reported by participants an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 7 days after study injection

  6. Number of Participants With Unsolicited Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 28 days after study injection

  7. Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation

    An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site. Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (Day 181) are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 through Day 181

Secondary outcomes

  1. Geometric Mean Fold-Rise (GMFR) of Antibodies for Influenza, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

    Time frame: Day 1, Day 29

  2. GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA

    SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

    Time frame: Day 1, Day 29

  3. GM Level of Antibodies for Influenza, as Measured by Microneutralization (MN) Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. The PPIS for MN assay included a subset of randomized participants who received study intervention to be tested for MN, complied with the timing of immunogenicity blood sampling collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

    Time frame: Day 29

  4. GMFR of Antibodies for Influenza, as Measured by MN Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. The PPIS for MN assay included a subset of randomized participants who received study intervention to be tested for MN, complied with the timing of immunogenicity blood sampling collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

    Time frame: Day 1, Day 29

Other outcomes

  1. Number of Deaths Related to Study Drug mRNA-1083 and Placebo

    A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, irrespective of its perceived relationship to the study drug. The Investigator assessed the causality by determining whether there was a reasonable possibility that the death was related to the study drug, using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable.

    Time frame: Day 1 through Day 181

  2. Number of Deaths Related to Control Drug Influenza Vaccine and COVID-19 Vaccine

    A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, irrespective of its perceived relationship to the study drug. The Investigator assessed the causality by determining whether there was a reasonable possibility that the death was related to the study drug, using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable.

    Time frame: Day 1 through Day 181

07

Results

Posted Jun 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
Started2025201220092015
Received both injections2011200619932005
Completed1974197719441957
Not completed51356558
Withdrew: Death2122
Withdrew: Lost to follow-up27183631
Withdrew: Physician decision0103
Withdrew: Protocol violation1121
Withdrew: Withdrawal by subject14111415
Withdrew: Other than specified73116

Outcome measures

PrimaryGeometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. The Per Protocol Immunogenicity Set (PPIS) included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative reverse transcription polymerase chain reaction (RT-PCR) test for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

Time frame:
Day 29
Reported as:
Geometric mean · titer
Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay
titerCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
Influenza A H1N1 Antibody120.5 (116.0 to 125.2)104.3 (100.4 to 108.4)137.7 (132.1 to 143.5)97.3 (93.4 to 101.5)
Influenza A H3N2 Antibody114.7 (110.4 to 119.2)107.9 (103.9 to 112.1)111.5 (107.5 to 115.7)80.8 (77.9 to 83.8)
Influenza B Victoria-lineage Antibody245.3 (237.8 to 252.9)219.4 (212.8 to 226.3)224.9 (218.0 to 232.0)185.0 (179.3 to 190.8)
Influenza B Yamagata-lineage Antibody93.3 (91.1 to 95.6)92.6 (90.4 to 94.9)101.7 (99.3 to 104.3)88.1 (86.0 to 90.3)
Statistical analysis
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.155 · 97.5% CI 1.086 to 1.229
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.155 · 95% CI 1.094 to 1.220
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.063 · 97.5% CI 0.999 to 1.130
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.063 · 95% CI 1.007 to 1.122
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.414 · 97.5% CI 1.322 to 1.513
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.414 · 95% CI 1.333 to 1.500
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.380 · 97.5% CI 1.300 to 1.465
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.380 · 95% CI 1.310 to 1.454
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.118 · 97.5% CI 1.063 to 1.175
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.118 · 95% CI 1.070 to 1.167
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.007 · 97.5% CI 0.969 to 1.047
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.007 · 95% CI 0.973 to 1.042
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.216 · 97.5% CI 1.156 to 1.278
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.216 · 95% CI 1.163 to 1.270
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.154 · 97.5% CI 1.109 to 1.201
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.154 · 95% CI 1.115 to 1.195
PrimaryGM Level of Antibodies for SARS-CoV-2, as Measured by Pseudovirus Neutralization Assay (PsVNA)

SARS-CoV-2 strain included Omicron XBB.1.5 antibody. The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

Time frame:
Day 29
Reported as:
Geometric mean · titer
GM Level of Antibodies for SARS-CoV-2, as Measured by Pseudovirus Neutralization Assay (PsVNA)
titerCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
GM Level of Antibodies for SARS-CoV-2, as Measured by Pseudovirus Neutralization Assay (PsVNA)1396.7 (1326.6 to 1470.5)851.1 (808.6 to 895.9)1551.6 (1476.3 to 1630.7)1186.1 (1128.5 to 1246.7)
Statistical analysis
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.641 · 95% CI 1.526 to 1.765
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.641 · 97.5% CI 1.510 to 1.783
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.308 · 95% CI 1.219 to 1.404
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Gmr: 1.308 · 97.5% CI 1.207 to 1.418
PrimaryInfluenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a Day 29 postinjection level ≥1:40 if Baseline was \<1:10 or a 4-fold or greater rise if Baseline was ≥1:10 in anti-hemagglutinin (HA) antibodies measured by HAI assay. The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

Time frame:
Baseline to Day 29
Reported as:
Number · percentage of participants
Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay
percentage of participantsCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
Influenza A H1N1 Antibody36.4 (34.3 to 38.7)31.1 (29.0 to 33.2)50.6 (48.3 to 52.9)32.7 (30.6 to 34.8)
Influenza A H3N2 Antibody38.7 (36.5 to 40.9)34.6 (32.5 to 36.8)41.9 (39.7 to 44.2)27.4 (25.4 to 29.5)
Influenza B Victoria-lineage Antibody23.9 (22.0 to 25.9)19.4 (17.6 to 21.2)25.8 (23.9 to 27.9)17.2 (15.5 to 19.0)
Influenza B Yamagata-lineage Antibody8.8 (7.5 to 10.1)10.2 (8.9 to 11.7)13.0 (11.5 to 14.6)10.3 (9.0 to 11.8)
Statistical analysis
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 5.4 · 95% CI 2.4 to 8.4
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 5.4 · 97.5% CI 1.9 to 8.8
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 4.0 · 95% CI 1.0 to 7.1
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 4.0 · 97.5% CI 0.5 to 7.6
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 4.5 · 95% CI 1.9 to 7.2
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 4.5 · 95% CI 1.5 to 7.5
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: -1.4 · 95% CI -3.3 to 0.4
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: -1.4 · 97.5% CI -3.6 to 0.7
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 17.9 · 95% CI 14.8 to 21.0
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 17.9 · 97.5% CI 14.3 to 21.4
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 14.6 · 95% CI 11.6 to 17.6
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 14.6 · 97.5% CI 11.1 to 18.0
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 8.6 · 95% CI 6.0 to 11.2
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 8.6 · 97.5% CI 5.6 to 11.6
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 2.7 · 95% CI 0.6 to 4.7
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 2.7 · 97.5% CI 0.3 to 5.0
PrimarySARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA

SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as a Day 29 postinjection level ≥4-fold rise if Baseline was ≥lower limit of quantification (LLOQ) or ≥4×LLOQ if Baseline value was \<LLOQ in the nAb values measured by PsVNA. LLOQ was 38 arbitrary unit (AU)/milliliter (mL). The PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

Time frame:
Baseline to Day 29
Reported as:
Number · percentage of participants
SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA
percentage of participantsCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA82.3 (80.5 to 84.1)69.6 (67.4 to 71.7)84.6 (82.8 to 86.2)76.5 (74.5 to 78.4)
Statistical analysis
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 12.8 · 95% CI 10.0 to 15.5
  • Cohort A1: mRNA-1083 and Placebo vs Cohort A2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 12.8 · 97.5% CI 9.6 to 15.9
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 8.1 · 95% CI 5.5 to 10.6
  • Cohort B1: mRNA-1083 and Placebo vs Cohort B2: Influenza Vaccine and COVID-19 Vaccine · Percentage difference: 8.1 · 97.5% CI 5.2 to 11.0
PrimaryNumber of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs (local and systemic) were reported by participants an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 7 days after study injection
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
Any1681156516981640
Grade 3 or Grade 418384246127
PrimaryNumber of Participants With Unsolicited Adverse Events (AEs)

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 28 days after study injection
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events (AEs)
ParticipantsCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
Number of Participants With Unsolicited Adverse Events (AEs)239250195191
PrimaryNumber of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation

An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site. Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (Day 181) are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 through Day 181
Reported as:
Count of participants · Participants
Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
ParticipantsCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
SAEs70522927
AESIs181349
MAAEs426428301304
AEs Leading to Discontinuation0010
SecondaryGeometric Mean Fold-Rise (GMFR) of Antibodies for Influenza, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

Time frame:
Day 1, Day 29
Reported as:
Geometric mean · ratio
Geometric Mean Fold-Rise (GMFR) of Antibodies for Influenza, as Measured by HAI Assay
ratioCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
Influenza A H1N1 Antibody2.70 (2.60 to 2.81)2.36 (2.26 to 2.46)3.70 (3.54 to 3.86)2.54 (2.43 to 2.66)
Influenza A H3N2 Antibody2.78 (2.67 to 2.89)2.59 (2.48 to 2.70)3.07 (2.95 to 3.19)2.22 (2.13 to 2.31)
Influenza B Victoria-lineage2.05 (1.98 to 2.12)1.84 (1.77 to 1.90)2.13 (2.06 to 2.20)1.75 (1.69 to 1.81)
Influenza B Yamagata-lineage1.52 (1.48 to 1.55)1.52 (1.48 to 1.56)1.71 (1.66 to 1.75)1.48 (1.44 to 1.52)
SecondaryGMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA

SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. PPIS included all randomized participants who received study intervention, complied with the timing of immunogenicity blood sample collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

Time frame:
Day 1, Day 29
Reported as:
Geometric mean · ratio
GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA
ratioCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA16.86 (15.87 to 17.93)10.32 (9.72 to 10.96)17.83 (16.78 to 18.94)13.56 (12.72 to 14.46)
SecondaryGM Level of Antibodies for Influenza, as Measured by Microneutralization (MN) Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. The PPIS for MN assay included a subset of randomized participants who received study intervention to be tested for MN, complied with the timing of immunogenicity blood sampling collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

Time frame:
Day 29
Reported as:
Geometric mean · titer
GM Level of Antibodies for Influenza, as Measured by Microneutralization (MN) Assay
titerCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
Influenza A H1N1 Antibody676.4 (528.8 to 865.3)635.9 (489.4 to 826.4)946.8 (729.7 to 1228.4)428.1 (327.0 to 560.4)
Influenza A H3N2 Antibody587.6 (483.9 to 713.6)668.8 (538.9 to 830.0)645.8 (519.1 to 803.5)393.9 (324.7 to 477.9)
Influenza B Victoria-lineage Antibody2845.4 (2406.1 to 3364.9)3072.5 (2571.0 to 3671.9)2901.5 (2457.6 to 3425.6)1883.1 (1571.4 to 2256.5)
Influenza B Yamagata-lineage Antibody1118.8 (910.4 to 1374.9)1434.4 (1200.9 to 1713.3)1449.6 (1222.5 to 1719.0)1071.3 (883.8 to 1298.4)
SecondaryGMFR of Antibodies for Influenza, as Measured by MN Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. The PPIS for MN assay included a subset of randomized participants who received study intervention to be tested for MN, complied with the timing of immunogenicity blood sampling collections to have both Baseline and Day 29 assessments using a window of -7 to +14 days, had no major dosing error, had negative RT-PCR test for influenza and SARS-CoV-2 on Day 1, and had no major protocol deviations or conditions/medications that affected the immune response.

Time frame:
Day 1, Day 29
Reported as:
Geometric mean · ratio
GMFR of Antibodies for Influenza, as Measured by MN Assay
ratioCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
Influenza A H1N1 Antibody4.89 (3.92 to 6.10)4.68 (3.68 to 5.94)8.74 (7.03 to 10.87)5.14 (4.01 to 6.60)
Influenza A H3N2 Antibody2.88 (2.44 to 3.41)2.46 (2.01 to 3.01)3.33 (2.76 to 4.01)1.94 (1.64 to 2.31)
Influenza B Victoria-lineage3.22 (2.63 to 3.94)3.02 (2.48 to 3.67)3.87 (3.27 to 4.58)3.27 (2.66 to 4.02)
Influenza B Yamagata-lineage2.98 (2.56 to 3.46)3.38 (2.75 to 4.15)3.66 (3.02 to 4.44)3.42 (2.79 to 4.19)
Other pre-specifiedNumber of Deaths Related to Study Drug mRNA-1083 and Placebo

A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, irrespective of its perceived relationship to the study drug. The Investigator assessed the causality by determining whether there was a reasonable possibility that the death was related to the study drug, using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable.

Time frame:
Day 1 through Day 181
Reported as:
Count of participants · Participants
Number of Deaths Related to Study Drug mRNA-1083 and Placebo
ParticipantsCohort A1: mRNA-1083 and PlaceboCohort B1: mRNA-1083 and Placebo
Deaths22
Deaths Related to Study Drug mRNA-108300
Other pre-specifiedNumber of Deaths Related to Control Drug Influenza Vaccine and COVID-19 Vaccine

A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, irrespective of its perceived relationship to the study drug. The Investigator assessed the causality by determining whether there was a reasonable possibility that the death was related to the study drug, using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable.

Time frame:
Day 1 through Day 181
Reported as:
Count of participants · Participants
Number of Deaths Related to Control Drug Influenza Vaccine and COVID-19 Vaccine
ParticipantsCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B2: Influenza Vaccine and COVID-19 Vaccine
Deaths12
Deaths Related to Control Drug00

Adverse events

Collected over Day 1 through Day 181. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A1: mRNA-1083 and Placebo2/2,025 (0.1%)71/2,011 (3.5%)0/2,011 (0%)
Cohort A2: Influenza Vaccine and COVID-19 Vaccine1/2,012 (0%)52/2,006 (2.6%)0/2,006 (0%)
Cohort B1: mRNA-1083 and Placebo2/2,009 (0.1%)29/1,993 (1.5%)0/1,993 (0%)
Cohort B2: Influenza Vaccine and COVID-19 Vaccine2/2,015 (0.1%)27/2,005 (1.3%)0/2,005 (0%)
Most frequent serious events
Showing 10 of 154
Most frequent serious events
EventCohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 Vaccine
Acute respiratory failureRespiratory, thoracic and mediastinal disorders4/20112/20060/19931/2005
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/20110/20063/19930/2005
PneumoniaInfections and infestations1/20113/20061/19933/2005
Atrial fibrillationCardiac disorders2/20113/20060/19931/2005
Cerebrovascular accidentNervous system disorders3/20110/20060/19930/2005
Non-cardiac chest painGeneral disorders3/20110/20061/19930/2005
Post-traumatic stress disorderPsychiatric disorders0/20110/20062/19930/2005
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/20111/20062/19932/2005
Cardiac arrestCardiac disorders0/20112/20061/19932/2005
Hypertensive urgencyVascular disorders0/20110/20060/19932/2005

Baseline characteristics

The randomization set included all participants who were randomly assigned. Participants were included in the treatment arm to which they were randomized.

Age, Continuous
Age, Continuous(years)Cohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 VaccineTotal
Mean70.9 ± 4.9670.7 ± 4.7057.5 ± 4.2557.4 ± 4.2164.1 ± 8.06
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 VaccineTotal
Female10841100116512014550
Male9419128448143511
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 VaccineTotal
Hispanic or Latino2842753933811333
Not Hispanic or Latino17011695159116136600
Unknown or Not Reported40422521128
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A1: mRNA-1083 and PlaceboCohort A2: Influenza Vaccine and COVID-19 VaccineCohort B1: mRNA-1083 and PlaceboCohort B2: Influenza Vaccine and COVID-19 VaccineTotal
Race — White15881570138213505890
Race — Black or African American3733705225551820
Race — Asian25375239153
Race — American Indian or Alaska Native912121346
Race — Native Hawaiian or Other Pacific Islander143513
Race — Other434819
Race — Multiple144192158
Race — Unknown/Not Reported1112152462
08

Study locations

146 sites
  • Pinnacle Research Group-409 E 10th St
    Anniston, Alabama 36207-4780, United States
  • Accel Research Site - Achieve - Birmingham
    Birmingham, Alabama 35216, United States
  • Cullman Clinical Trials
    Cullman, Alabama 35055-1902, United States
  • Desert Clinical Research - CCT - PPDS
    Mesa, Arizona 85213-5226, United States
  • Foothills Research Center - CCT - PPDS
    Phoenix, Arizona 85044-6097, United States
  • Headlands Research - Scottsdale - PPDS
    Scottsdale, Arizona 85260-6411, United States
  • Scottsdale Clinical Trials
    Scottsdale, Arizona 85260-6742, United States
  • Fiel Family & Sports Medicine - PC - CCT - PPDS
    Tempe, Arizona 85283-1528, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - Cerritos
    Cerritos, California 90703-2544, United States
  • Long Beach Research Institute, LLC
    Long Beach, California 90805-4587, United States
  • CenExel Apex (CNS) - Los Alamitos - PPDS
    Los Alamitos, California 90720-3118, United States
  • Central Valley Research, LLC
    Modesto, California 95350-5365, United States
  • Carbon Health- NoHo West Urgent Care and Primary Care
    North Hollywood, California 91606-3287, United States
  • Empire Clinical Research
    Pomona, California 91767-1800, United States
  • Artemis Institute For Clinical Research LLC - Riverside - Headlands - PPDS
    Riverside, California 92503-4955, United States
  • Clinical Innovations Trials - Riverside - CenExel - PPDS
    Riverside, California 92506-3257, United States
  • Peninsula Research Associates - Headlands - PPDS
    Rolling Hills Estates, California 90274-7604, United States
  • Artemis Institute For Clinical Research LLC - San Diego - Headlands - PPDS
    San Diego, California 92103-2204, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - Vista
    Vista, California 92083-6051, United States
  • Tekton Research - Fort Collins - PPDS
    Fort Collins, Colorado 80525-5752, United States
  • Tekton Research - Longmont - PPDS
    Longmont, Colorado 80501-6461, United States
  • Stamford Therapeutics Consortium - ERN - PPDS
    Stamford, Connecticut 06905-5316, United States
  • Chase Medical Research LLC - Waterbury
    Waterbury, Connecticut 06708-3346, United States
  • Revival Research Corporation
    Doral, Florida 33122-1902, United States
  • Indago Research and Health Center
    Hialeah, Florida 33012, United States
  • CenExel RCA - Hollywood
    Hollywood, Florida 33024-2709, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Jacksonville Center For Clinical Research
    Jacksonville, Florida 32216, United States
  • Health Awareness - Jupiter - ERN - ERN
    Jupiter, Florida 33458-2775, United States
  • Accel Research Sites - Saint Petersburg - Largo - ERN - PPDS
    Largo, Florida 33777-1359, United States
  • Flourish Research - Leesburg - PPDS
    Leesburg, Florida 34748-5077, United States
  • Accel Research Sites - Maitland
    Maitland, Florida 32751-7258, United States
  • AES - DRS - Optimal Research Florida - Melbourne
    Melbourne, Florida 32934-8172, United States
  • Suncoast Research Group LLC - Flourish - PPDS
    Miami, Florida 33135-1687, United States
  • St. Johns Center for Clinical Research - ERN - PPDS
    Saint Augustine, Florida 32086-5775, United States
  • ForCare Clinical Research - CenExel FCR - PPDS
    Tampa, Florida 33613-1244, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - Atlanta
    Atlanta, Georgia 30328-4018, United States
  • DelRicht Research, LLC - Springer Wellness & Restorative - Atlanta - PPDS
    Atlanta, Georgia 30329-2201, United States
  • iResearch Atlanta - CenExel - PPDS
    Decatur, Georgia 30030-3438, United States
  • Javara, Inc./Privia Medical Group Georgia, LLC - Fayetteville - Javara - PPDS
    Fayetteville, Georgia 30214, United States
  • Georgia Clinic - CCT - PPDS
    Norcross, Georgia 30092-4544, United States
  • Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS
    Savannah, Georgia 31406-3928, United States
  • Clinical Research Atlanta - ERN - PPDS
    Stockbridge, Georgia 30281-9054, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - Chicago
    Chicago, Illinois 60602-3960, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607-4559, United States
  • Flourish Research - Andersonville - PPDS
    Chicago, Illinois 60640-2781, United States
  • Koch Family Medicine
    Morton, Illinois 61550-2495, United States
  • AES - DRS - Optimal Research Illinois - Peoria
    Peoria, Illinois 61614, United States
  • DM Clinical Research - Chicago - ERN - PPDS
    River Forest, Illinois 60305-1876, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - Evansville
    Evansville, Indiana 47714-7513, United States
  • Velocity Clinical Research - Valparaiso (Buynak Clinical Research) - PPDS
    Valparaiso, Indiana 46383-2195, United States
  • The Iowa Clinic, P.C. - West Des Moines Campus
    West Des Moines, Iowa 50266-8216, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219-1389, United States
  • Delricht Overland Park
    Overland Park, Kansas 66223-4857, United States
  • Tekton Research - Wichita - PPDS
    Wichita, Kansas 67218-2913, United States
  • DelRicht Research, LLC - Louisville - PPDS
    Louisville, Kentucky 40205-3162, United States
  • Versailles Family Medicine - CCT - PPDS
    Versailles, Kentucky 40383-1947, United States
  • Velocity Clinical Research (Baton Rouge - Louisiana) - PPDS
    Baton Rouge, Louisiana 70809-3416, United States
  • Velocity Clinical Research - Covington - PPDS
    Covington, Louisiana 70433-7237, United States
  • DelRicht Clinical Research, LLC - The Murphy Clinic - PPDS
    Mandeville, Louisiana 70471, United States
  • IMA Clinical Research - Monroe, LA - PPDS
    Monroe, Louisiana 71201-3915, United States
  • DelRicht Clinical Research, LLC - New Orleans - ClinEdge - PPDS
    New Orleans, Louisiana 70115-3584, United States
  • DelRicht Research, LLC - Internal - Baton Rouge - PPDS
    Prairieville, Louisiana 70769-4222, United States
  • Annapolis Internal Medicine - CCT - PPDS
    Annapolis, Maryland 21401-7050, United States
  • Advanced Primary Care & Geriatric Care - CCT - PPDS
    Rockville, Maryland 20850-6246, United States
  • DelRicht Clinical Research, LLC - Matthew Mintz, MD - PPDS
    Rockville, Maryland 20852-3803, United States
  • Velocity Clinical Research (Rockville - Maryland) - PPDS
    Rockville, Maryland 20854-2960, United States
  • Privia Medical Group, LLC - Columbia Pike - Silver Spring - Javara - PPDS
    Silver Spring, Maryland 20901-4402, United States
  • DM Clinical Research - The Brook House - ERN - PPDS
    Brookline, Massachusetts 02445-7113, United States
  • Headlands Research - Detroit - Headlands - PPDS
    Southfield, Michigan 48034-1088, United States
  • Great Lakes Research Institute
    Southfield, Michigan 48075-5400, United States
  • DM Clinical Research - Southfield - ERN - PPDS
    Southfield, Michigan 48076-5412, United States
  • Mankato Clinic - Premier Drive - Javara - PPDS
    Mankato, Minnesota 56001-6076, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - Minneapolis
    Richfield, Minnesota 55423-2590, United States
  • DelRicht Research, LLC - Gulfport - PPDS
    Gulfport, Mississippi 39503-4176, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - St. Louis
    Creve Coeur, Missouri 63141-7084, United States
  • Clay Platte Family Medicine - CCT Research
    Kansas City, Missouri 64151-2411, United States
  • Clinvest - National Ave - Headlands - PPDS
    Springfield, Missouri 65807-6012, United States
  • DelRicht Research, LLC - Command Family Medicine - Springfield - DelRicht - PPDS
    Springfield, Missouri 65807-7303, United States
  • Sundance Clinical Research - ERN - PPDS
    St Louis, Missouri 63141-7068, United States
  • DelRicht Clinical Research, LLC - MS. Medicine - PPDS
    Town and Country, Missouri 63017-8209, United States
  • Skyline Medical Center - PC - CCT - PPDS
    Elkhorn, Nebraska 68022-2889, United States
  • Methodist Physicians Clinic - CCT Research - PPDS
    Fremont, Nebraska 68025-2592, United States
  • Velocity Clinical Research (Lincoln - Nebraska) - PPDS
    Lincoln, Nebraska 68510-4855, United States
  • Velocity Clinical Research
    Omaha, Nebraska 68134, United States
  • Midwest Regional Health Services - LLC - CCT - PPDS
    Omaha, Nebraska 68144, United States
  • Papillion Research Center
    Papillion, Nebraska 68046-4194, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - Henderson
    Henderson, Nevada 89052-3992, United States
  • Santa Rosa Urgent Care - Primary Care - CCT - PPDS
    Las Vegas, Nevada 89119-5483, United States
  • Las Vegas Clinical Trials
    North Las Vegas, Nevada 89030-7187, United States
  • Hassman Research Institute - HRI - Berlin - CenExel - PPDS
    Berlin, New Jersey 08009, United States
  • Velocity Clinical Research - Albuquerque - PPDS
    Albuquerque, New Mexico 87107-4503, United States
  • AXCES Research Group - Sante Fe - ERN - PPDS
    Santa Fe, New Mexico 87505-4753, United States
  • DM Clinical Research - Brooklyn
    Brooklyn, New York 11220-5906, United States
  • AES - DRS - Synexus Clinical Research US, Inc. - New York
    New York, New York 10017-4008, United States
  • Rochester Clinical Research, Inc
    Rochester, New York 14609-3173, United States
  • DelRicht Research, LLC - Charlotte - PPDS
    Charlotte, North Carolina 28205-5078, United States
  • Tryon Medical Partners, PLLC and Javara Inc. - Javara - PPDS
    Charlotte, North Carolina 28287-3884, United States
  • Monroe Biomedical Research -343 Venus St
    Monroe, North Carolina 28112-4025, United States
  • Trial Management Associates LLC - ERN - PPDS
    Wilmington, North Carolina 28403-6235, United States

Showing the first 100 of 146 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kostanyan L, Wu I, Sinkiewicz M, Cardona J, Johnson K, Das R. Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults >/=50 years. Hum Vaccin Immunother. 2026 Dec;22(1):2675021. doi: 10.1080/21645515.2026.2675021. Epub 2026 May 29. PubMed 42213900 ↗
  • Rudman Spergel AK, Wu I, Deng W, Cardona J, Johnson K, Espinosa-Fernandez I, Sinkiewicz M, Urdaneta V, Carmona L, Schaefers K, Girard B, Paila YD, Mehta D, Callendret B, Kostanyan L, Ananworanich J, Miller J, Das R, Shaw CA. Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults >/=50 Years: A Randomized Clinical Trial. JAMA. 2025 Jun 10;333(22):1977-1987. doi: 10.1001/jama.2025.5646. PubMed 40332892 ↗
  • Sanchez-Martinez ZV, Alpuche-Lazcano SP, Stuible M, Akache B, Renner TM, Deschatelets L, Dudani R, Harrison BA, McCluskie MJ, Hrapovic S, Blouin J, Wang X, Schuller M, Cui K, Cho JY, Durocher Y. SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice. Vaccine. 2024 Dec 2;42(26):126463. doi: 10.1016/j.vaccine.2024.126463. Epub 2024 Oct 30. PubMed 39481241 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in May 2024, 7 months.

Results were first posted in Jun 2025, 1 year after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 7 months is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Oct 24, 2023
StartActual
Oct 19, 2023
Primary completionActual
May 28, 2024
CompletionActual
May 28, 2024
Results first posted
Jun 13, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06097273
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Oct 19, 2023
Primary completion
May 28, 2024
Completion
May 28, 2024
Results posted
Jun 13, 2025
Last update
Jul 1, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MRNA-1083

Start the discussion